As the industry enters the fourth quarter, how do new drug approvals by FDA’s Center for Drug Evaluation and Research stand now and comparative to recent trends? What is the mix between small molecules and biologics? DCAT Value Chain Insights looks at the products and companies.

With its pending $7.3-billion deal to acquire the bio/pharmaceutical company, Metsera, Pfizer is making a strong play in the obesity drug market. What are the assets that Pfizer will be acquiring, and how do they stack up against the other notable contenders in the obesity drug market?

The US Supreme Court is set to hear oral arguments on November 5, 2025, in a case examining the legal authority of the current Administration to impose tariffs under the International Emergency Economic Powers Act, which was used to impose reciprocal tariffs on a country-by-country basis. What may be next?